HCW Biologics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company uses its Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the senescence-associated phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9218 is being evaluated in two clinical trials. HCW9302 is designed to activate and expand regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors.
More about the company